OBJECTIVE: To evaluate the impact of statin use on the incidence of advanced age-related macular degeneration (AMD) and its components, choroidal neovascularization (CNV) and geographic atrophy (GA), among patients with bilateral large drusen. DESIGN: Cohort study within a multicenter, randomized, clinical trial. PARTICIPANTS: Patients enrolled in the Complications of Age-related Macular Degeneration Prevention Trial (CAPT). METHODS: Eligibility criteria for the clinical trial required that participants have >or=10 large (>125 microm) drusen and visual acuity >or=20/40 in each eye. Patients scheduled for their final CAPT visit after May 2005 were interviewed on their history of use of cholesterol-lowering medications, including statins. Trained readers identified CNV and end point GA (>1 Macular Photocoagulation Study disc area of GA) based on review of fluorescein angiograms and fundus photographs taken at annual follow-up visits and when patients reported symptoms. The risk ratio for participants developing CNV or developing GA associated with statin use was estimated with time-dependent Cox proportional hazards models. MAIN OUTCOME MEASURES: Development of advanced AMD, CNV, and end point GA. RESULTS: Among 764 patients eligible for the interview, 744 (97.4%) patients completed the interview on medication use. Statin use was reported by 296 (39.8%) of those interviewed, with the majority, 187 (63.2%) of the 296, beginning use after enrollment in CAPT. Among 744 patients, advanced AMD developed in 332 (22.5%) eyes of 242 (32.5%) patients, CNV in 222 (15%) eyes of 176 (23.7%) patients, and GA in 114 (7.7%) eyes of 80 (10.8%) patients. With adjustment for other risk factors, the estimated risk ratio for eyes (95% confidence interval) associated with statin use was 1.15 (0.87-1.52) for advanced AMD, 1.35 (0.99-1.83) for CNV, and 0.80 (0.46-1.39) for GA. CONCLUSIONS: The CAPT data are not consistent with a strong protective effect (risk ratio, <or=0.85) of statins on the development of advanced AMD among patients with bilateral large drusen.
RCT Entities:
OBJECTIVE: To evaluate the impact of statin use on the incidence of advanced age-related macular degeneration (AMD) and its components, choroidal neovascularization (CNV) and geographic atrophy (GA), among patients with bilateral large drusen. DESIGN: Cohort study within a multicenter, randomized, clinical trial. PARTICIPANTS: Patients enrolled in the Complications of Age-related Macular Degeneration Prevention Trial (CAPT). METHODS: Eligibility criteria for the clinical trial required that participants have >or=10 large (>125 microm) drusen and visual acuity >or=20/40 in each eye. Patients scheduled for their final CAPT visit after May 2005 were interviewed on their history of use of cholesterol-lowering medications, including statins. Trained readers identified CNV and end point GA (>1 Macular Photocoagulation Study disc area of GA) based on review of fluorescein angiograms and fundus photographs taken at annual follow-up visits and when patients reported symptoms. The risk ratio for participants developing CNV or developing GA associated with statin use was estimated with time-dependent Cox proportional hazards models. MAIN OUTCOME MEASURES: Development of advanced AMD, CNV, and end point GA. RESULTS: Among 764 patients eligible for the interview, 744 (97.4%) patients completed the interview on medication use. Statin use was reported by 296 (39.8%) of those interviewed, with the majority, 187 (63.2%) of the 296, beginning use after enrollment in CAPT. Among 744 patients, advanced AMD developed in 332 (22.5%) eyes of 242 (32.5%) patients, CNV in 222 (15%) eyes of 176 (23.7%) patients, and GA in 114 (7.7%) eyes of 80 (10.8%) patients. With adjustment for other risk factors, the estimated risk ratio for eyes (95% confidence interval) associated with statin use was 1.15 (0.87-1.52) for advanced AMD, 1.35 (0.99-1.83) for CNV, and 0.80 (0.46-1.39) for GA. CONCLUSIONS: The CAPT data are not consistent with a strong protective effect (risk ratio, <or=0.85) of statins on the development of advanced AMD among patients with bilateral large drusen.
Authors: G S Hageman; P J Luthert; N H Victor Chong; L V Johnson; D H Anderson; R F Mullins Journal: Prog Retin Eye Res Date: 2001-11 Impact factor: 21.198
Authors: Hilary L Wilson; Daniel M Schwartz; Hilarey R F Bhatt; Charles E McCulloch; Jacque L Duncan Journal: Am J Ophthalmol Date: 2004-04 Impact factor: 5.258
Authors: Norimitsu Ban; Tae Jun Lee; Abdoulaye Sene; Zhenyu Dong; Andrea Santeford; Jonathan B Lin; Daniel S Ory; Rajendra S Apte Journal: J Lipid Res Date: 2018-06-26 Impact factor: 5.922
Authors: D T Q Barbosa; T S Mendes; H R Cíntron-Colon; S Y Wang; R B Bhisitkul; K Singh; S C Lin Journal: Eye (Lond) Date: 2014-02-07 Impact factor: 3.775
Authors: Shaza N Al-Holou; William R Tucker; Elvira Agrón; Traci E Clemons; Catherine Cukras; Frederick L Ferris; Emily Y Chew Journal: Ophthalmology Date: 2015-10-04 Impact factor: 12.079
Authors: Joseph Thomas; Sohail Mohammad; Richard Charnigo; Judit Baffi; Ahmed Abdel-Latif; Khaled M Ziada Journal: South Med J Date: 2015-08 Impact factor: 0.954